Roth Capital Initiates Coverage on Sophiris Bio Inc(NASDAQ:SPHS). The shares have been rated Buy. The rating by Roth Capital was issued on Sep 15, 2016.
In a different note, PiperJaffray said it Initiates Coverage on Sophiris Bio Inc, according to a research note issued on Aug 30, 2016. The shares have been rated ‘Overweight’ by the firm. PiperJaffray said it Initiates Coverage on Sophiris Bio Inc, according to a research note issued on Aug 30, 2016. The shares have been rated ‘Overweight’ by the firm.
Sophiris Bio Inc (SPHS) made into the market gainers list on Tuesdays trading session with the shares advancing 4.48% or 0.13 points. Due to strong positive momentum, the stock ended at $3.03, which is also near the day’s high of $3.08. The stock began the session at $2.95 and the volume stood at 18,60,136 shares. The 52-week high of the shares is $8.55 and the 52 week low is $0.67. The company has a current market capitalization of $69 M and it has 2,26,18,436 shares in outstanding.
Sophiris Bio Inc(SPHS) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-0.21.
Several Insider Transactions has been reported to the SEC. On Jan 23, 2015, Lars Ekman (director) sold 9,663 shares at $0.47 per share price.
Sophiris Bio Inc. formerly Protox Therapeutics Inc. is a Canada-based biopharmaceutical company focused on the research development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate PRX302 which has completed three clinical trials for the treatment of BPH as well as two clinical trials for the treatment of localized recurrent prostate cancer.